Arbutus Biopharma (ABUS) Asset Writedowns and Impairment (2015 - 2019)

Arbutus Biopharma has disclosed Asset Writedowns and Impairment across 5 years of filings, most recently posting $43.8 million for Q3 2019.

• Asset Writedowns and Impairment for Q3 2019 came in at $43.8 million, up 195.97% year-over-year; the trailing twelve-month figure through Dec 2020 was $43.8 million (down 25.25% YoY), and the FY2019 annual result was $43.8 million, up 195.97% from the prior year.
• Asset Writedowns and Impairment came in at $43.8 million for Q3 2019 at Arbutus Biopharma, up from $14.8 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $156.3 million in Q2 2016 to a low of $1.0 million in Q4 2015.
• The 5-year median for Asset Writedowns and Impairment is $40.8 million (2017), against an average of $55.9 million.
• Across the five-year window, Asset Writedowns and Impairment jumped 9425.37% in 2016 and slumped 57.89% in 2017, its largest moves.
• Arbutus Biopharma's Asset Writedowns and Impairment stood at $1.0 million in 2015, then surged by 9425.37% to $96.9 million in 2016, then plunged by 57.89% to $40.8 million in 2017, then sank by 63.7% to $14.8 million in 2018, then surged by 195.97% to $43.8 million in 2019.
• The last three Asset Writedowns and Impairment figures came in at $43.8 million (Q3 2019), $14.8 million (Q3 2018), and $40.8 million (Q4 2017), per Business Quant data.